/pharmaceuticals/oncology/Replicate-Bioscience-raises-40-million/99/i33 20210910 Concentrates 99 33 /magazine/99/09933.html Replicate Bioscience raises $40 million for RNA therapies rna, pharmaceuticals, drug discovery con bus Ryan Cross pharmaceuticals oncology business start-ups biological-chemistry rna Replicate raises cash for RNA therapies Chemical & Engineering News Replicate Bioscience raises $40 million for RNA therapies Replicate Bioscience raises $40 million for RNA therapies
by Ryan Cross | September 10, 2021
New York City–based Kadmon develops immuno-oncology therapies and drugs for fibrotic diseases. It makes the recently approved Rezurock (belumosudil), a small molecule that inhibits a protein implicated in graft-versus-host disease. Sanofi says the acquisition will bolster its general medicines portfolio, which includes two transplant-related therapies.
by Megha Satyanarayana | September 10, 2021
Trillium is an immuno-oncology company with two lead proteins in clinical trials that could serve as checkpoint inhibitors. In 2020, Pfizer invested $25 million in Trillium through its Breakthrough Growth Initiative. /pharmaceuticals/biologics/Pfizer-buy-immunotherapy-company-Trillium/99/i31 20210830 Concentrates 99 31 /magazine/99/09931.html Pfizer to buy immunotherapy company Trillium immunotherapy, cancer, biologics con bus Megha Satyanarayana pharmaceuticals biologics Pfizer has agreed to buy Trillium Therapeutics and its cancer checkpoint inhibitors, which recognize CD47 on a cancer cell (pink), encouraging immune cells (blue) to attack tumors.
by Megha Satyanarayana | August 30, 2021
/pharmaceuticals/Shanique-Borteley-Alabi/99/i30 20210820 Molecular matchmaker is designing drugs that break down badly behaving proteins 99 30 /magazine/99/09930.html C&EN’s 2021 Talented 12: Shanique Borteley Alabi Profile, Alabi, talented 12 scitech Laura Howes pharmaceuticals pharmaceuticals oncology people profiles Alabi and coworkers created a proteolysis-targeting chimera (PROTAC) that breaks down cancer-causing forms of the protein BRAF while sparing healthy ones.
by Laura Howes | August 20, 2021
Lilly also announced the merger of Loxo Oncology, which it acquired in 2019, with its oncology unit. /pharmaceuticals/Lilly-separates-neuroscience-research-group/99/i30 20210819 Concentrates 99 30 /magazine/99/09930.html Lilly separates a neuroscience research group pharmaceuticals, research and development, neuroscience, immunology, oncology con bus Rick Mullin pharmaceuticals Lilly separates neuroscience R&D Chemical & Engineering News Lilly separates a neuroscience research group Lilly separates a neuroscience research group
by Rick Mullin | August 19, 2021
“True risk means true money on the table, and sometimes the CROs overvalue the input they can give,” says Robert Boyle, the CEO of Sentinel Oncology, a biotech in Cambridge, England, that outsources all its chemistry research. Sentinel has done one risk-sharing agreement, with O2h, in the 16 years since its foundation.
by Vanessa Zainzinger, special to C&EN | August 08, 2021
—Lilly, Kumquat to partner on small molecules for immunotherapy “” Loxo Oncology, which is owned by Eli Lilly and Company, is partnering with Kumquat Biosciences to develop small-molecule immunotherapies. Lilly will pay Kumquat $70 million up front, with up to $2 billion in milestone payments. Kumquat will use its small-molecule-developing technology to identify potential antitumor candidates, and Lilly will further develop what it deems the most promising. /business/Lilly-Kumquat-partner-small-molecules/99/i29 20210807 Concentrates 99 29 /magazine/99/09929.html Lilly, Kumquat to partner on small molecules for immunotherapy immunotherapy, oncology, drug discovery con bus Megha Satyanarayana business pharmaceuticals oncology Lilly to partner with Kumquat Chemical & Engineering News Lilly, Kumquat to partner on small molecules for immunotherapy Lilly, Kumquat to partner on small molecules for immunotherapy
by Megha Satyanarayana | August 07, 2021
The two firms, which began collaborating in 2014, have advanced three immuno-oncology and neurodegeneration programs to clinical trials. More than 20 early-stage programs are in the works. Each firm will commit an additional $500 million to the effort, and Calico will helm research and early development until 2025.
by Ryan Cross | July 31, 2021
/pharmaceuticals/oncology/Pfizer-pays-1-billion-develop/99/i27 20210723 Concentrates 99 27 /magazine/99/09927.html Pfizer pays $1 billion to develop Arvinas protein degrader Pine chemicals, Australia con bus Michael McCoy pharmaceuticals oncology biological-chemistry cancer pharmaceuticals Pfizer pays $1 billion to develop Arvinas drug Chemical & Engineering News Pfizer pays $1 billion to develop Arvinas protein degrader Pfizer pays $1 billion to develop Arvinas protein degrader
by Michael McCoy | July 23, 2021
Bicycle is developing the synthetic short peptides as oncology treatments. But Ionis will use them to deliver oligonucleotide therapeutics to tissue, taking advantage of the high affinity for the transferrin receptor of some of Bicycle’s peptides. Bicycle will retain rights to use the peptides for all nonoligonucleotide delivery applications.
by Michael McCoy | July 18, 2021